Press release

July 28, 2026 National Stock Exchange of India Limited BSE Limited Plot No. C/1, “G” Block, Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai 400 051 Mumbai 400 001 Symbol: RPGLIFE Security Code: 532983 Dear Sirs /Madam, Sub: Press Release - Financial Results Please find enclosed herewith a copy of press release with respect to unaudited Financial Results of the Company for the quarter ended June 30, 2026. Kindly take the above on record. Thanking you, Yours Sincerely, For RPG Life Sciences Limited Rajesh Shirambekar Head- Legal & Company Secretary Encl: as above RPG Lifesciences Revenue grows at 15.8% in Q1 along with robust EBITDA margin expansion to 24.5%  Revenue grew 15.8%, EBITDA by 17.9% and margins by 40 bps y-o-y in Q1 FY27  Domestic Formulations outperformed the Indian pharma market growth rate, grew at 14.8% vs 11.6% of the market  Margin expansion on the back of operating discipline, strategic launches, field-force effectiveness and key therapy focus  RPG Life Sciences enters “Top 50 Indian Pharma Companies” in June 2026; becomes 5th fastest growing company in IPM Mumbai, 29 July 2026: RPG Life Sciences Limited today announced its financial results for the quarter ended 30th June, 2026. Key Financials Particulars Q1 FY27 Q1 FY26 Growth Revenue from Operations ₹195.7 Cr ₹168.9 Cr 15.8% EBITDA ₹48.0 Cr ₹40.7 Cr 17.9% EBITDA Margin 24.5% 24.1% +40 bps The Company commenced FY27 with healthy growth and profitability in Q1. Revenue from Operations increased 15.8% to ₹195.7 crore, while EBITDA grew 17.9% to ₹48.0 crore. EBITDA margin improved to 24.5%, reflecting continued operating discipline, despite a challenging external environment. The Domestic Formulations business continued its strong momentum and delivered 14.8% growth during the quarter, ahead of the broader Indian Pharma Market growth of 11.6%. This was supported by key therapy focus, new product introductions, field-force effectiveness, among other strategic initiatives. RPG Life Sciences also entered the coveted list of Top 50 Indian pharmaceutical companies in June 2026*. International Formulations registered 7.7% growth during the quarter while the API business delivered 35.6% growth during the quarter on the back of unit coming back to operations. Commenting on the results and business outlook, Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., said: “We have started FY27 on a strong note continuing our track record of market-beating performance and growth. Our Domestic Formulations business continued to outperform the market and helped the company enter the Top 50 ranking in the Indian Pharma Market, an important milestone in our growth journey. Going forward, we remain focused on strengthening our international presence through market expansion and new customer onboarding along with scaling up our API operations that can drive the next wave of growth of us. Backed by strong balance sheet, healthy profitability and continued investment in talent, we remain confident of sustaining our growth momentum in the long-term.” Other key achievements this quarter:  Naprosyn grew at 16% this quarter along with double-digit growth of key baskets like nephrology and rheumatology among others.  Recognized as ‘Top Nephrology Company- 2026’ by India Pharma Outlook  Recognized for ‘Best Use of AI in Sales Force Effectiveness’ by Bluetech Media  Received ‘Excellence in Breakthrough Pharmaceutical Innovations’ by Network 7 Media *Source: Pharmarack MAT June 2026 Database RPG Life Sciences Ltd (www.rpglifesciences.com) RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company produces a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients. RPG Group (www.rpggroup.com) RPG Group, established in 1979, is one of India’s fastest-growing business groups with a turnover of US$ 5.2 billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses. Media Contact Rashmi Menon – 88980 20577 | rashmi@rpg.in